2133417-13-5
Chemical Structure
Ralmitaront
Synonym(s): RO6889450
- CAS No.: 2133417-13-5
- Formula:C17H22N4O2
- Molecular Weight:314.38
IUPAC Name: (S)-5-ethyl-4-methyl-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-3-carboxamide
InChIKey: XHHXGKRFUPEPFM-OAHLLOKOSA-N
SMILES: O=C(C1=NNC(CC)=C1C)NC2=CC=C([C@H]3CNCCO3)C=C2
Biological Activity: Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ralmitaront | 99.92% | Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ralmitaront (Standard) | ≥98% | Ralmitaront (Standard) is the analytical standard of Ralmitaront (HY-109157). This product is intended for research and analytical applications. Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Linda S Brady, et al. Redirecting the revolution: new developments in drug development for psychiatry. Expert Opin Drug Discov. 2019 Dec;14(12):1213-1219. [Content Brief]
- [2]. Halff EF, et al. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023 Jan;46(1):60-74. [Content Brief]
- [3]. Ågren R, et al. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics. Int J Neuropsychopharmacol. 2023 Sep 25;26(9):599-606. [Content Brief]
- [4]. Yu J, et al. Elucidating the molecular pharmacology of trace amine-associated receptor 1 to advance antipsychotic drug discovery. Clin Transl Med. 2024 Feb;14(2):e1576. [Content Brief]
